Venus Remedies Ltd Stock Analysis

BSE: 526953 | NSE: VENUSREM | Pharmaceuticals & Drugs | Small Cap

BSE Share Price 02-Dec-2022 18:01
198.85 -0.70 (-0.35%)

DeciZen - Make an Informed Decision on Venus Remedies

Overall Rating
M-Cap below 500cr. High Risk from low Liquidity

1. Quality

2. Valuation

Fair

3. Price Trend

Venus Remedies Price Chart

P/E Ratio (CD) :
14.83
Market Cap :
265.8 Cr.
52-wk low :
178.7
52-wk high :
531
Bole Toh?

1. Is Venus Remedies Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Venus Remedies Ltd is a average quality company.

2. Is Venus Remedies Ltd undervalued or overvalued?

The key valuation ratios of Venus Remedies Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Venus Remedies Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Venus Remedies Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Venus Remedies:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Venus Remedies Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
ROCE % 12.7%12.1%4.4%3.7%0.9%-0.9%-1.1%0.6%10%7.8%-
Value Creation Index -0.1-0.1-0.7-0.7-0.9-1.1-1.1-1.0-0.3-0.4-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 469542464418400372322339548599549
YoY Gr. Rt. %-15.6%-14.3%-9.9%-4.4%-6.9%-13.6%5.4%61.5%9.2%-
Adj EPS 54.356.24.41.5-15-24.9-20.1-4.633.127.113.5
YoY Gr. Rt. %-3.4%-92.1%-66.9%-1121.8%NANANANA-18%-
BVPS (₹) 355.1403.4399.1382.5314.9293.2269.4262313.2329.5337.3
Adj Net Profit 57.364.35.11.7-18.5-30.8-24.8-5.740.836.218
Cash Flow from Ops. 52.252.767.846.958.931.245.377.613241-
Debt/CF from Ops. 5.25.54.77.25.39.86.62.80.41-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 2.8%8.4%23%9.2%
Adj EPS -7.4%NANA-18%
BVPS -0.80.96.95.2
Share Price -3.8% 13.2% 106% -54.7%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
Return on Equity % 16.715.31.10.4-4.5-8.2-7.1-1.711.38.64.1
Op. Profit Mgn % 25.625.519.219.412.710.610.1129.810.48.3
Net Profit Mgn % 12.211.91.10.4-4.6-8.3-7.7-1.77.56.13.3
Debt to Equity 0.70.60.70.80.80.90.90.70.10.10.1
Working Cap Days 177197251270270285337338188152190
Cash Conv. Cycle 1061071351531521531701477055136

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 22.98%

Return on Equity has declined versus last 3 years average to 4.10%

Net Profit has been subdued in last 3 years 0.00%

Sales growth is not so good in last 4 quarters at 2.18%

Latest Financials - Venus Remedies Ltd.

Standalone Consolidated
TTM EPS (₹) 21.8 13.5
TTM Sales (₹ Cr.) 525 549
BVPS (₹.) 350.4 337.3
Reserves (₹ Cr.) 455 437
P/BV 0.57 0.60
PE 9.14 14.83
From the Market
52 Week Low / High (₹) 178.65 / 531.00
All Time Low / High (₹) 1.00 / 638.50
Market Cap (₹ Cr.) 266
Equity (₹ Cr.) 13.4
Face Value (₹) 10
Industry PE 37.8

Management X-Ray of Venus Remedies :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *100.00100.0095.4818.7415.220.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Venus Remedies

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)

News

Venus Remedies Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Venus Remedies on 02-Dec-2022 18:01 is : 198.8.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 02-Dec-2022 18:01 the market cap of Venus Remedies stood at ₹ 265.8.
The latest PE ratio of Venus Remedies as of 02-Dec-2022 18:01 is 9.14.
The latest PB ratio of Venus Remedies as of 02-Dec-2022 18:01 is 0.57
The 52-week high of Venus Remedies is ₹ 531.0 and the 52-week low is ₹ 178.7.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Venus Remedies is ₹ 525.4 ( Cr.) .

About Venus Remedies Ltd

Venus Remedies incorporated in 1989, is a pharmaceutical manufacturing company. The company provides formulations in area of anti-biotics and oncological therapeutics.

Company has two manufacturing facilities located in India and Germany. Company manufactures Oncological and Cefelosporine Injectable products.

Its manufacturing facility located in India has received ISO 9001, ISO, 14001 and OHSAS 18001 for quality management. Its Germany facility follows EU-GMP norms.

Presently, the company has successfully made its presence in the markets of Philippines, Thailand, Malaysia, Cambodia, Burma, Vietnam, Sri Lanka, Pakistan, Bangladesh, Nepal, Uganda, Kenya, Botswana, Zimbabwe, Sudan, Mauritius, Yemen, Iraq, Russia, Belarus, Ukraine, Costa Rica, Venezuela, Guatemala, Peru, Colombia, Ecuador, Syria, Yeman, Togo, Saudi Arbia and Iraq.

Company has entered into strategic alliances with various pharmaceutical companies to launch its R&D based specialty products. It has tie-ups with companies namely IPCA Laboratories, Elder Pharmaceuticals, Shreya Lifesciences, Cadila Healthcare, Glenmark Pharmaceuticals, Marksans Pharma, Indoco Remedies, Karle Health Sciences, Lupin and Jagsonpal Pharmaceuticals.

Company also conducts in-house research and development activities that focuses Formulation Development, NDDS (Novel Drug Delivery System), new formulations of off patented chemicals and analytical and chemical research.

Products

The company is engaged in manufacturing products catering various segments such as Oncology, Cephalosporins, Carbapenems and Other Specialties, Intravenous Products, Vials/Lyophilized Injectables, Pre-Filled Syringes, Hormones, Ampoules and Biological Products.

Milestone/ Awards

2009
Venus Remedies - Product Patent for "TOBRACEF" granted in South Africa.
Venus Bags Another Product Patent from South Africa for POTENTOX.
2010
Venus Remedies receives GMP Certification from Botswana".
Venus Remedies ties up with IMTECH and Panjab Univ to develop Typhoid detection kits.
The Company has received approval from the Reserve Bank of India for rollover of FCCB USD 5mn, with YTM @4% with maturity till February 15, 2015.
Venus Remedies research Blockbuster "Sulbactomax" gets European Union Patent"
2011
Venus Remedies Ltd wins Gold Medal for TROIS under DST - Lockheed Martin India Innovation Growth Program 2011.
Venus launches its patented research product ACHNIL” in India.
Venus Remedies wins ""India Manufacturing Excellence Award 2011.
2012
Venus Remedies introduces "Ready-to-Use"" Single Vial Taxedol in India
Venus Remedies Limited introduced TROIS that is a research based, patent protected topical nano-emulsion product in India
The Company has won Manufacturing Award for its world class manufacturing and operational excellence at the "Industry 2.0 Manufacturing Innovation Conclave 2012.
Venus wins Patent award in Silver Category.

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now